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Histidine‑rich glycoprotein 
as a prognostic biomarker for sepsis
Kosuke Kuroda1*, Kenzo Ishii2, Yuko Mihara1, Naoya Kawanoue1, Hidenori Wake3, 
Shuji Mori4, Michihiro Yoshida5, Masahiro Nishibori6 & Hiroshi Morimatsu1
Various biomarkers have been proposed for sepsis; however, only a few become the standard. We 
previously reported that plasma histidine‑rich glycoprotein (HRG) levels decreased in septic mice, 
and supplemental infusion of HRG improved survival in mice model of sepsis. Moreover, our previous 
clinical study demonstrated that HRG levels in septic patients were lower than those in noninfective 
systemic inflammatory response syndrome patients, and it could be a biomarker for sepsis. In this 
study, we focused on septic patients and assessed the differences in HRG levels between the non‑
survivors and survivors. We studied ICU patients newly diagnosed with sepsis. Blood samples were 
collected within 24 h of ICU admission, and HRG levels were determined using an enzyme‑linked 
immunosorbent assay. Ninety‑nine septic patients from 11 institutes in Japan were included. HRG 
levels were significantly lower in non‑survivors (n = 16) than in survivors (n = 83) (median, 15.1 
[interquartile ranges, 12.7–16.6] vs. 30.6 [22.1–39.6] µg/ml; p < 0.01). Survival analysis revealed 
that HRG levels were associated with mortality (hazard ratio 0.79, p < 0.01), and the Harrell C‑index 
(predictive power) for HRG was 0.90. These results suggested that HRG could be a novel prognostic 
biomarker for sepsis.
Abbreviations
APACHE  Acute physiology and chronic evaluation
CI  Confidence interval
ELISA  Enzyme-linked immunosorbent assay
HR  Hazard ratio
HRG  Histidine-rich glycoprotein
ICU  Intensive care unit
IQR  Interquartile ranges
PCT  Procalcitonin
SIRS  Systemic inflammatory response syndrome
SOFA  Sequential organ failure assessment
Sepsis is one of the leading causes of death  worldwide1,2. However, all clinical trials conducted for the develop-
ment of therapeutic drugs for sepsis for decades have failed. One of the problems hindering an early initiation 
of treatment for sepsis is unavailability of a good biomarker to diagnose and evaluate severity of  sepsis3. Many 
markers and scoring systems have been studied to predict the severity and mortality in septic patients. Procal-
citonin (PCT) is commonly used to assist in the diagnosis of acute infection in clinical  settings4,5 and is some-
what considered as a prognostic  biomarker6,7. However, a single biomarker cannot sufficiently determine the 
 prognosis3,7,8. Thus, new biomarkers available to estimate sepsis severity and enable earlier treatment initiation 
are highly anticipated.
Histidine-rich glycoprotein (HRG) is a 75 kDa plasma glycoprotein produced in the liver and present at 
concentration of approximately 100 µg/ml9. It is considered to be involved in many functions in biological 
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systems, such as coagulation, immune response, and modulation of  angiogenesis9,10. In particular, HRG is sug-
gested to play an essential role in host defense  mechanisms10–12. Recently, we reported that plasma HRG levels 
rapidly decreased in mice with  sepsis13. Moreover, supplemental HRG infusion significantly improved the sepsis 
survival rate in mice, while the knockdown of HRG levels exacerbated  mortality13. Since HRG strongly induced 
the spherical shape in human neutrophils, suppressed the neutrophil adhesion to vascular endothelial cells, 
maintained passage through microcapillaries, and reduced ROS production, these effects may contribute to the 
beneficial effects of HRG detected in septic  animals13. Furthermore, HRG has been recently reported to protect 
the vascular endothelial cells from LPS-induced disorder and increased  permeability14. Our animal study as well 
as in vitro experiments suggested that plasma HRG might be a useful biomarker of sepsis and that supplemental 
therapy with HRG may provide a novel strategy for the treatment of sepsis. In fact, our previous clinical study 
on 70 patients with systemic inflammatory response syndrome (SIRS) showed that HRG levels of septic patients 
were significantly lower than those of noninfective SIRS patients and that HRG levels were significantly associ-
ated with mortality within the SIRS  population15. However, whether HRG could predict the prognosis of septic 
patients remains unclear.
This study included septic patients according to Sepsis-2  definition16 and evaluate the survival rate of septic 
patients classified according to plasma HRG levels. HRG levels were also compared with clinical parameters 
such as PCT in septic patients.
Results
Patients. Patients were prospectively enrolled from October 2014 to September 2016 in 11 Japanese hos-
pitals: 2 university and 9 general hospitals. Written informed consent was obtained from 101 patients. Two 
were excluded because of lack of 28-day survival data, and finally, 99 patients were analyzed. The patient char-
acteristics are shown in Table 1 and Supplementary Tables S1 and S2. The median age was 72.0 (interquartile 
ranges [IQR], 64.0–78.0) years and 70% were males (69 males and 30 females). Their median acute physiology 
and chronic evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores were 25.0 (IQR, 
21.0–31.0) and 11.0 (IQR, 8.0–13.0), respectively. The 28-day mortality rate was 16.2% (16/99 cases). A total of 
46 patients (46.5%) were diagnosed with septic shock, 43 (43.4%) with severe sepsis, and 10 (10.1%) with sepsis 
according to the Sepsis-2 definition. The 28-day mortality rates in patients with septic shock, severe sepsis, and 
sepsis were 17.4% (8/46 patients), 18.6% (8/43 patients), 0% (0/10 patients), respectively.
Plasma HRG and PCT levels on the first day of ICU admission. The median HRG level of 99 septic 
patients was 26.49 (IQR, 19.55–38.40) µg/ml in this study.
Table 1.  Patient characteristics. Expressed as median (interquartile range). APACHE acute physiology and 
chronic evaluation, SOFA sequential organ failure assessment, AIDS acquired immunodeficiency syndrome.
Variable Total Sepsis Severe sepsis Septic shock
N 99 10 43 46
Age, years 72.0 (64.0–78.0) 75.0 (68.3–80.5) 72.0 (64.0–80.0) 71.0 (60.8–76.3)
Male sex, n 69 (69.7%) 8 (80.0%) 28 (65.1%) 33 (71.7%)
28-day death, days 16 (16.2%) 0 8 (18.6%) 8 (17.4%)
ICU stay, days 10.0 (5.0–16.0) 7.5 (3.8–15.5) 11.0 (5.0–18.0) 9.5 (5.0–16.0)
APACHE II score 25.0 (21.0–31.0) 20.0 (13.5–21.8) 24.0 (22.0–30.0) 28.0 (21.5–34.5)
SOFA score 11.0 (8.0–13.0) 4.5 (2.0–6.0) 9.0 (7.0–12.0) 13.0 (11.0–16.0)
Source of infection, n (death) 99 (16)
Lung 20 (4) 3 7 (2) 10 (2)
Gastrointestinal 19 (2) 3 10 (1) 6 (1)
Hepatic 1 0 0 1
 Gallbladder 8 0 3 5
 Urinary 14 (1) 1 6 (1) 7
 Bone/soft tissue 13 (2) 2 5 (1) 6 (1)
Others 24 (7) 1 12 (3) 11 (4)
Ventilation, n 53 (53.5%) 5 (50.0%) 23 (53.5%) 25 (54.3%)
Inotropes (Day 1) 54 (54.5%) 1 (10.0%) 7 (16.3%) 46 (100%)
Blood purification
Chronic dialysis 4 (4.0%) 0 1 (2.3%) 3 (6.5%)
Renal replacement therapy 29 (29.3%) 0 15 (34.9%) 14 (30.4%)
Polymyxin B hemoperfusion 7 (7.1%) 0 3 (7.0%) 4 (8.7%)
Liver failure 2 (2.0%) 0 2 (4.7%) 0
AIDS 0 0 0 0
Hematologic malignancies 6 (6.1%) 1 (10.0%) 1 (2.3%) 4 (8.7%)
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Figure 1 shows the primary outcome results. Comparing the non-survivors (n = 16) and survivors (n = 83), 
HRG levels in the former were significantly lower than those in the latter (median, 15.1 [IQR, 12.7–16.6] vs. 30.6 
[22.1–39.6] µg/ml; Mann–Whitney test, P < 0.01). PCT levels in non-survivors and survivors were 9.23 (IQR, 
3.30–100) and 31.8 (11.0–84.2) ng/ml, respectively, but without statistical differences (P = 0.42).
HRG levels in patients with septic shock, severe sepsis, and sepsis were 25.5 (IQR, 17.6–37.6), 30.8 (19.6–40.9), 
and 28.9 (22.2–37.8) µg/ml, respectively, but without statistical differences (Kruskal–Wallis test, P = 0.48) (Sup-
plementary Figure S1).
There were no significant correlations between HRG levels and other parameters, such as white blood cell 
count (Spearman’s rho, 0.071, P = 0.48), C-reactive protein (− 0.0018, P = 0.99), PCT (0.089, P = 0.38), platelet 
number (0.039, P = 0.70), and fibrinogen (0.066, P = 0.55).
Survival analysis. Table 2 shows associations between plasma levels of each marker and mortality. Higher 
first-day HRG levels were significantly associated with lower risk of mortality. The hazard ratio (HR) was 0.79 
(95% confidence interval [CI], 0.71–0.87, P < 0.01). Even after adjusting with the APACHE II score, the golden 
standard in evaluating the patient’s severity, the HRG level remained an independent prognostic factor (adjusted 
HR, 0.81; 95% CI, 0.72–0.89; P < 0.01). PCT levels were not statistically associated with mortality (P = 0.81). The 
Harrell C-index for mortality was as follows: HRG, 0.90 (95% CI, 0.81–0.99); PCT, 0.54 (0.37–0.71); APACHE II 
score, 0.72 (0.58–0.86); and SOFA score, 0.68 (0.56–0.81).
When patients were divided into four subgroups according to quartiles of HRG level, Kaplan–Meier curves 
(Fig. 2A) showed that the mortality in the Q1 group (lowest HRG subgroup) was significantly higher than that 
in others (log-rank test, Bonferroni corrected P < 0.01).
Supplementary Table S3 shows that the sensitivity and specificity of HRG levels associated with mortality at 
the cut-off level of 20.0 µg/ml was 0.94 and 0.84, respectively. Thus, when patients were divided into high and 
low HRG groups according to this cut-off level, Kaplan–Meier curves (Fig. 2B) showed that the mortality in the 
latter group was significantly higher than that in the former (HR, 57.2; 95% CI, 11.5–1034; P < 0.01).
We analyzed whether HRG was associated with mortality, regardless of the severity of organ dysfunction. 
Supplementary Figure S2 shows the associations between HRG level and mortality in subgroups stratified with 
Figure 1.  Plasma HRG levels in septic patients on the first day of ICU admission. We compared HRG levels 
between survivors (n = 83) and non-survivors (n = 16). A box-and-whisker plot showing median, 25th, and 75th 
percentiles. The bars represent the 5th and 95th percentiles. Circles represent HRG levels in patients. ***P < 0.01. 
HRG histidine-rich glycoprotein.
Table 2.  Associations between each variable and mortality. We used Cox’s proportional hazard model to 
evaluate associations between each variable and mortality. HRG histidine-rich glycoprotein, PCT procalcitonin, 
APACHE Acute Physiology and Chronic Evaluation, SOFA Sequential Organ Failure Assessment, HR hazard 
ratio, Adjusted HR hazard ratio adjusted according to APACHE II score.
Variables
Univariate analysis Adjusted with APACHE II score
HR (95% CI) P Harrell C-index Adjusted HR (95% CI) P
HRG 0.79 (0.71–0.87) < 0.01 0.90 0.81 (0.72–0.89) < 0.01
PCT 0.9993 (0.99–1.00) 0.81 0.54 NA NA
APACHE II score 1.12 (1.06–1.20) < 0.01 0.72 NA NA
SOFA score 1.19 (1.04–1.37) 0.010 0.68 NA NA
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APACHE II score and each parameter of SOFA score: shock, respiratory dysfunction, liver dysfunction, renal 
dysfunction, and platelet number. HRG levels were shown to be significantly associated with mortality in all 
subgroups.
Discussion
In this multicenter prospective study, first-day HRG levels in non-survivors were demonstrated to be significantly 
lower than those in survivors among septic patients. HRG levels were also shown to be significantly associated 
with mortality, and determination of HRG provided a good prognostic estimation as a biomarker for sepsis. 
Moreover, these properties could also be found in patients with organ failure, such as severe hepatic or renal 
failure.
In our previous investigation, 70 patients with SIRS, including 20 with sepsis, were examined. We showed 
that HRG levels in septic patients were significantly lower than those in noninfective SIRS patients and that 
Figure 2.  Kaplan–Meier survival curves. (A) Patients were divided into four subgroups according to quartiles 
of HRG level; Q1, 6.49–19.5 µg/ml, n = 25; Q2, 19.6–26.5 µg/ml, n = 25; Q3, 26.6–38.2 µg/ml, n = 25; Q4, 
38.3–78.0 µg/ml, n = 24. The mortality of the Q1 group was significantly higher than others (log-rank test, 
Bonferroni corrected P < 0.01). (B) Patients were divided into high and low HRG groups according to the cut-off 
level of 20.0 µg/ml. At the cut-off level of 20.0 µg/ml, the sensitivity and specificity of HRG levels associated with 
mortality was 0.94 and 0.84, respectively. HRG histidine-rich glycoprotein.
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HRG levels were significantly associated with mortality within the SIRS  population15. However, the association 
of HRG with sepsis survival was difficult to determine due to the limited sample  size17. In the current study, we 
focused on sepsis and investigated a new cohort of 99 septic patients from 11 institutes, and we could obtain 
similar results. Thus, these results were reproducible in independent cohorts.
In this study, first-day HRG levels were shown to be associated with mortality. Harrell C-index, the predictive 
power index, for mortality was 0.90 for HRG. This C-index was superior to the C-indices of APACHE II (0.72) 
and SOFA scores (0.68), the golden standards in evaluating the sepsis severity. The SOFA score is included in 
the new definition of sepsis (Sepsis-3)18, and previous studies demonstrated that SOFA score is a good indicator 
of prognosis in ICU-admitted critically ill patients, especially those with severe  sepsis19–21. Conversely, Liu et al. 
reported in their meta-analysis that PCT was associated with mortality in septic patients and can moderately 
predict sepsis  mortality6. However, the prognostic accuracy of PCT has been reported to be inadequate for 
clinical use, especially in patients with renal  failure22,23. In the current study, the C-index for PCT was 0.54 and 
inferior to that for HRG. Therefore, we suggest that HRG might be superior to APACHE II score, SOFA score, 
and PCT as a prognostic biomarker.
First-day HRG levels were found to distinguish survivors from non-survivors. Kaplan–Meier curves (Fig. 2A) 
clearly showed that only Q1 group, patients with first-day HRG levels of < 19.5 µg/ml, had high mortality rate 
of ≥ 50% and that almost all patients in other groups survived. This unique property would facilitate the determi-
nation of death threshold when using HRG as a biomarker. In other words, HRG was thought to identify patients 
who really need intensive treatments. Intensive and timely care for patients with first-day HRG levels of < 19.5 µg/
ml may possibly reduce sepsis mortality. In addition, our previous animal study suggested that supplemental 
infusion of HRG might provide a novel strategy for the treatment of  sepsis13, indicating that HRG might serve 
as a therapeutic as well as a biomarker.
Moreover, when patients were divided into subgroups according to the degree of organ dysfunctions, reduced 
HRG levels were shown to be significantly associated with mortality in all subgroups, including hepatic and renal 
dysfunction (Supplementary Figure S2). Current sepsis biomarkers have problems in evaluating patients with 
organ  failure7. There are some cases in which PCT cannot work well, especially in patients with renal  failure7,23. 
Our data suggested that HRG had sufficient ability in evaluating the severity of septic patients in these settings, 
including hepatic and renal failures. These results strongly suggested that plasma HRG would be a useful prog-
nostic biomarker for sepsis.
This study had some limitations. First, the old definition of sepsis (Sepsis-2) was used because this study was 
started before the Sepsis-3 definition was established. Old data could affect interpretation of our results. In this 
study, all patients had suspicious infection and SOFA score of 2 or higher, however it is unclear whether it was 
increase of > 2 score. Therefore, another study should be conducted using the Sepsis-3 definition, and we have 
already started the study. Second, although we focused on sepsis survival, we studied 99 septic patients, includ-
ing 16 non-survivors. To reinforce our claim that HRG could be a prognostic marker for sepsis, a larger study 
should be conducted. Third, we had no data on exact number of eligible patients and the incidence rate of sepsis 
in 11 hospitals. Selection bias could affect the results. Fourth, only one-time HRG levels were assessed on day 1 
of ICU, and we had no data on the time course and the exact timing of blood sampling. Timing of sampling in 
consideration of treatment, and time-dependent changes in HRG levels would be more valuable and may reflect 
treatment effects. Whether HRG-guided therapy is possible with time course data may be evaluated. Fifth, we 
had no data regarding patient comorbidities and the pathogen. Further investigations on the association of HRG 
with patient characteristics and with the causes of sepsis will be conducted. Sixth, because of the lack of exact 
data on the cause of death, it is possible that patients with withdrawal from treatment were included, which could 
affect the results. Seventh, for measuring HRG, we used our in-house ELISA, which established in our previously 
published study. This may affect the results of this study.
In conclusion, in this study, first-day plasma HRG levels in non-survivors were found to be significantly lower 
than those in survivors among septic patients. HRG were also found to have a good prognostic accuracy as a 
biomarker for sepsis. Therefore, we suggest that HRG might be a good biomarker in diagnosing sepsis, evaluating 
sepsis severity, and predicting patient outcomes. Studies with larger cohorts are needed to confirm our findings.
Methods
Study design. This was a multicenter, prospective, and observational investigation approved by the 
Institutional Review Board of any institution involved, including the Okayama University Graduate School 
of Medicine, Dentistry, and Pharmaceutical Sciences. It was registered at the UMIN Clinical Trials Registry 
(UMIN000017651, registered 22 May 2015—retrospectively registered, principal investigator’s name is Hiroshi 
Morimatsu). This study was performed in accordance with the ethical standards laid down in the Declaration of 
Helsinki and its later amendments. This observational study was also reported following the Strengthening the 
Reporting of Observational Studies in Epidemiology  guidelines24.
Patients and data collection. Patients who were newly diagnosed with sepsis according to Sepsis-216 
were prospectively enrolled in the study. The inclusion criteria were patients admitted to the ICU and the occur-
rence of sepsis. The exclusion criteria were age younger than 20 years, pregnancy, or failure to obtain consent.
Clinical and laboratory data were obtained daily while in the ICU. Initial SOFA score and APACHE II score 
were calculated using clinical parameters and blood test results. Patients were classified according to the previous 
definitions of sepsis (Sepsis-2), the guidelines of the American College of Chest Physicians/Society of Critical 
Care Medicine and the International Surviving Sepsis Campaign Guidelines  Committee16. A follow-up at 28 days 
was performed to determine survivors and non-survivors.
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Measurement methods. After obtaining written informed consent for participation from the patients or 
their relatives, blood samples were collected in tubes containing  K2-EDTA at a convenient timing within 24 h of 
sepsis diagnosis, regardless of the treatment. The samples were processed and immediately frozen in each hospi-
tal, then transported to Okayama University, and stored at − 80 °C for later analysis.
HRG levels were determined using a modified quantitative sandwich enzyme-linked immunosorbent assay 
(ELISA) as described  previously15. In brief, we used a rat monoclonal antibody against human HRG (made in-
house, number 75-14) as the capture antibody and horseradish peroxidase-conjugated nickel–nitrilotriacetic 
acid (Ni–NTA HRP conjugate; Qiagen, Venlo, Netherland) for detection instead of secondary antibody. Plasma 
samples were diluted 1:50 in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) for 
measurement. A standard curve is established using serial dilutions of known amounts of purified HRG (made 
in-house). Each plasma sample was tested in duplicate, and assays were repeated twice independently.
Outcomes. The primary outcome was HRG levels in survivors and non-survivors. The secondary outcome 
was the association between HRG levels and mortality.
Statistical analysis. The statistical approach was mostly designed a priori. Only the analysis provided in 
Supplementary Figure S2 arose out of the data exploration process and was therefore designed post hoc.
The median, interquartile ranges (IQR, 25th–75th percentiles), and box-whisker plot were used to sum-
marize the variables. The ICU first-day markers were compared using the Mann–Whitney/Kruskal–Wallis tests 
between/among subgroups, and the statistical significance level was set as 0.05 (two-sided). The contribution of 
each marker to the 28-day mortality was assessed using Cox’s proportional hazard model adjusted with APACHE 
II score, also especially in case of HRG, stratified with each parameter of SOFA score. The hazard ratio (HR) 
and 95% confidence interval (CI) were estimated. The cumulative survival rate was estimated and tested using 
the Kaplan–Meier method and the log-rank test with Bonferroni correction for four subgroups according to 
quartiles of HRG level, and using the Kaplan–Meier method and the log-rank test for subgroups defined by the 
cut-off value of HRG specified with the logistic regression receiver operating characteristic analysis; the HR was 
calculated using the Cox’s proportional hazard model. Spearman rank correlation coefficient was calculated 
to assess correlations between HRG and other variables. All analyses were performed using the JMP Pro 12 
software (SAS Institute Inc., Chicago, IL), except for the Harrell C-index that was performed using the STATA 
12 software (SAS Institute Inc.).
Data availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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